Home > > > Report Detail

Global Alpha 1 Antitrypsin Deficiency Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Publisher Name :
Date: 13-Sep-2021
No. of pages: 95

The Alpha 1 Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Alpha 1 Antitrypsin Deficiency Treatment size is estimated to be USD 2410.6 million in 2026 from USD 1732.2 million in 2020, with a change XX% between 2020 and 2021. The global Alpha 1 Antitrypsin Deficiency Treatment market size is expected to grow at a CAGR of 8.6% for the next five years.

Market segmentation

Alpha 1 Antitrypsin Deficiency Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

- Augmentation Therapy

- Cystic Fibrosis(CF)

- Non-CF Bronchiectasis(NCFB)

- Diabetes

- Other

Market segment by Application, can be divided into

- COPD

- Cystic Fibrosis(CF)

- Non-CF Bronchiectasis(NCFB)

- Diabetes

Market segment by players, this report covers

- Pfizer

- GlaxoSmithKline

- AstraZeneca

- Boehringer Ingelheim

- Teva Pharmaceutical Industries

- Takeda

- Baxter

- Grifols

- CSL Behring

- Kamada Ltd

- Chiesi Pharmaceuticals

- Kedrion Group

- Vertex Pharmaceuticals

- ProMetic Life Sciences

Market segment by regions, regional analysis covers

- North America (United States, Canada, and Mexico)

- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

- South America (Brazil, Argentina, Rest of South America)

- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Alpha 1 Antitrypsin Deficiency Treatment, with revenue, gross margin and global market share of Alpha 1 Antitrypsin Deficiency Treatment from 2019 to 2021.

Chapter 3, the Alpha 1 Antitrypsin Deficiency Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, indication and end users, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Alpha 1 Antitrypsin Deficiency Treatment research findings and conclusion, appendix and data source.

Global Alpha 1 Antitrypsin Deficiency Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment
1.2 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Indication
1.2.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2020
1.2.3 Augmentation Therapy
1.2.4 Cystic Fibrosis(CF)
1.2.5 Non-CF Bronchiectasis(NCFB)
1.2.6 Diabetes
1.2.7 Other
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Forecast
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast by Region
1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region, (2016-2021)
1.5.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
1.6.2 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
1.6.3 Alpha 1 Antitrypsin Deficiency Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim Recent Developments and Future Plans
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.6 Takeda
2.6.1 Takeda Details
2.6.2 Takeda Major Business
2.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Takeda Recent Developments and Future Plans
2.7 Baxter
2.7.1 Baxter Details
2.7.2 Baxter Major Business
2.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Baxter Recent Developments and Future Plans
2.8 Grifols
2.8.1 Grifols Details
2.8.2 Grifols Major Business
2.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Grifols Recent Developments and Future Plans
2.9 CSL Behring
2.9.1 CSL Behring Details
2.9.2 CSL Behring Major Business
2.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 CSL Behring Recent Developments and Future Plans
2.10 Kamada Ltd
2.10.1 Kamada Ltd Details
2.10.2 Kamada Ltd Major Business
2.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Kamada Ltd Recent Developments and Future Plans
2.11 Chiesi Pharmaceuticals
2.11.1 Chiesi Pharmaceuticals Details
2.11.2 Chiesi Pharmaceuticals Major Business
2.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Chiesi Pharmaceuticals Recent Developments and Future Plans
2.12 Kedrion Group
2.12.1 Kedrion Group Details
2.12.2 Kedrion Group Major Business
2.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Kedrion Group Recent Developments and Future Plans
2.13 Vertex Pharmaceuticals
2.13.1 Vertex Pharmaceuticals Details
2.13.2 Vertex Pharmaceuticals Major Business
2.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Vertex Pharmaceuticals Recent Developments and Future Plans
2.14 ProMetic Life Sciences
2.14.1 ProMetic Life Sciences Details
2.14.2 ProMetic Life Sciences Major Business
2.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 ProMetic Life Sciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.2.2 Top 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2016-2021)
5.2 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
6.3.2 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
7.3.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.3 France Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2016-2026)
8.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.5 India Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
9.2 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
9.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
9.3.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 9. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 13. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 17. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 21. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Industries Major Business
Table 24. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 25. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Takeda Corporate Information, Head Office, and Major Competitors
Table 27. Takeda Major Business
Table 28. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 29. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Baxter Corporate Information, Head Office, and Major Competitors
Table 31. Baxter Major Business
Table 32. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 33. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Grifols Corporate Information, Head Office, and Major Competitors
Table 35. Grifols Major Business
Table 36. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 37. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 39. CSL Behring Major Business
Table 40. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 41. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Kamada Ltd Corporate Information, Head Office, and Major Competitors
Table 43. Kamada Ltd Major Business
Table 44. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 45. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Chiesi Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Chiesi Pharmaceuticals Major Business
Table 48. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 49. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Kedrion Group Corporate Information, Head Office, and Major Competitors
Table 51. Kedrion Group Major Business
Table 52. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 53. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Vertex Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Vertex Pharmaceuticals Major Business
Table 56. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 57. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. ProMetic Life Sciences Corporate Information, Head Office, and Major Competitors
Table 59. ProMetic Life Sciences Major Business
Table 60. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 61. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Players (2019-2021)
Table 63. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2019-2021)
Table 64. Breakdown of Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
Table 66. Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions in the Past Five Years
Table 67. Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
Table 68. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Type (2016-2021)
Table 69. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2016-2021)
Table 70. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Type (2021-2026)
Table 71. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021)
Table 72. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Application (2021-2026)
Table 73. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication in 2020
Figure 3. Augmentation Therapy
Figure 4. Cystic Fibrosis(CF)
Figure 5. Non-CF Bronchiectasis(NCFB)
Figure 6. Diabetes
Figure 7. Other
Figure 8. Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users in 2020
Figure 9. COPD Picture
Figure 10. Cystic Fibrosis(CF) Picture
Figure 11. Non-CF Bronchiectasis(NCFB) Picture
Figure 12. Diabetes Picture
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2016-2026)
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region in 2020
Figure 17. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Figure 23. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Figure 24. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. AstraZeneca Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim Recent Developments and Future Plans
Figure 29. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 30. Takeda Recent Developments and Future Plans
Figure 31. Baxter Recent Developments and Future Plans
Figure 32. Grifols Recent Developments and Future Plans
Figure 33. CSL Behring Recent Developments and Future Plans
Figure 34. Kamada Ltd Recent Developments and Future Plans
Figure 35. Chiesi Pharmaceuticals Recent Developments and Future Plans
Figure 36. Kedrion Group Recent Developments and Future Plans
Figure 37. Vertex Pharmaceuticals Recent Developments and Future Plans
Figure 38. ProMetic Life Sciences Recent Developments and Future Plans
Figure 39. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players in 2020
Figure 40. Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 41. Global Top 3 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2020
Figure 42. Global Top 10 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2020
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 44. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type in 2020
Figure 45. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Type (2021-2026)
Figure 46. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application in 2020
Figure 47. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Application (2021-2026)
Figure 48. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 49. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 50. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 51. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 55. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 56. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 57. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 63. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2016-2026)
Figure 65. China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 72. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 73. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 77. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 78. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 79. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs